News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
19.17 ^USD	-1.94%		-5.75%	+0.16%

Mar. 20	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
Feb. 27	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	Apr. 09	GL
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	Apr. 09	AQ
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	Mar. 21	GL
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	Mar. 21	AQ
Myriad Genetics Gets US Patent for SneakPeek Snap Device	Mar. 20	MT
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device	Mar. 20	GL
Myriad: Q4 Earnings Snapshot	Feb. 27	AQ
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	Feb. 27	MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	Feb. 27	MT
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	Feb. 27	GL
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	Feb. 27	AQ
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27	CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3	Feb. 27	GL
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	Feb. 21	GL
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health	Feb. 15	GL
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health	Feb. 01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Summary

Filters